Recent Updates
Recently added Catalysts
ALT Positive Sentiment Score: 70/100

Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference

Tuesday, October 1, 2024 1 min read
Key Takeaway: Altimmune, Inc. announced its participation in the H.C. Wainwright 8th Annual MASH Virtual Conference, where CEO Vipin Garg and CMO Scott Harris will present. The conference is scheduled for October 7, 2024, at 11:30 a.m. EDT. This indicates Altimmune's active engagement in the biopharmaceutical community and its focus on developing peptide-based therapeutics, including pemvidutide, aimed at treating obesity and metabolic dysfunction-associated steatohepatitis.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a notable virtual conference highlights company visibility.
  • Leadership involvement suggests confidence in company's direction and strategies.
  • Focus on innovative therapies shows commitment to addressing healthcare needs.

Full Press Release Details

GAITHERSBURG, Md., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that its Chief Executive Officer, Vipin Garg, Ph.D., and Chief Medical Officer, Scott Harris, M.D., will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference:
Conference: H.C. Wainwright 8 th Annual MASH Virtual Conference
Presenters: Vipin Garg, Ph.D., Chief Executive Officer
Scott Harris, M.D., Chief Medical Officer
Date/Time: Monday, October 7, 2024, at 11:30 a.m. EDT
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
President and Chief Executive Officer
Inizio Evoke, Biotech
Danielle.cantey@inizioevoke.com
jweilman@burnsmc.com
This press release was published by a CLEAR® Verified individual.

Frequently Asked Questions

When is the Altimmune fireside chat scheduled?

The Altimmune fireside chat is on October 7, 2024, at 11:30 a.m. EDT.

Who will present at the Altimmune conference?

Vipin Garg, Ph.D., and Scott Harris, M.D., will present at the conference.

What is pemvidutide developed for?

Pemvidutide is a dual receptor agonist for obesity and MASH treatment.

How can I access the webcast of the session?

The webcast can be accessed on the Events section of the Altimmune website.

What type of company is Altimmune, Inc.?

Altimmune, Inc. is a clinical-stage biopharmaceutical company.

Tags: ALT Viatris Investor Conferences Healthcare Altimmune MASH Conference pemvidutide biopharmaceutical Vipin Garg
Last updated: Oct 1, 2024